Drug intelligence / Profile preview

Prostrolane

Development stage: Preclinical
Lead developer: Caregen
Modality: Peptides
Administration: Intraarticular

Overview

Prostrolane is an intra-articular peptide product developed by CAREGEN Co. Ltd. It contains sodium hyaluronate (1.5%) along with a blend of several peptides, specifically oligopeptide-92, nanopeptide-25, octapeptide-11, heptapeptide-16, and decapeptide-23. It is indicated for the treatment of knee osteoarthritis, aiming to provide pain relief and functional improvement. Its proposed mechanism involves inhibiting cartilage degeneration and stimulating the differentiation and proliferation of chondrocytes, in addition to the viscosupplementation provided by hyaluronic acid.

Brand names: Prostrolane

Targets

RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)

Beyond the preview

Go deeper on Prostrolane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostrolane.

Explore the full profile